For research use only, not for therapeutic use.
BMN-673(Cat No.:I000776), also known as talazoparib, is a small molecule inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP). PARP is a protein involved in the DNA damage response pathway, repairing damaged DNA and preventing the accumulation of mutations. By inhibiting the activity of PARP, BMN-673 can selectively target cancer cells that have defects in DNA repair pathways, such as those with BRCA mutations. This leads to the accumulation of DNA damage and ultimately cell death. BMN-673 has been approved by the FDA for the treatment of advanced ovarian cancer and breast cancer in patients with BRCA mutations, and it is being studied in clinical trials for the treatment of other types of cancer.
| Catalog Number | I000776 |
| CAS Number | 1207456-01-6 |
| Synonyms | Talazoparib; BMN-673 |
| Molecular Formula | C₁₉H₁₄F₂N₆O |
| Purity | 98% |
| Target | PARP |
| Target Protein | |
| Solubility | DMSO 75 mg/mL; Water <1 mg/mL; Ethanol <1 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | PARP2:0.87 nM (Ki)PARP1:1.2 nM (Ki) |
| IUPAC Name | (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one |
| InChI | InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1 |
| InChIKey | HWGQMRYQVZSGDQ-HZPDHXFCSA-N |
| SMILES | CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F |
| Reference | 1: Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven 2: de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev 3: Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE. Discovery and 4: Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec <br> |
